Tata 1mg FY26 revenue rises 23% to Rs 2,936 crore; combined loss narrows to Rs 287 crore

Tata 1mg’s FY26 consolidated revenue climbed from Rs 2,392 crore in FY25. Its healthcare solutions unit generated Rs 2,440 crore in revenue, while the technology unit posted Rs 496 crore in revenue and Rs 23 crore net profit.

— Source publishedTue, 28 Jul, 2026, 12:36 IST·First seen Tue, 28 Jul, 2026, 12:38 IST·Source Entrackr

What happened

Tata 1mg’s FY26 revenue rose 23% to Rs 2,936 crore while its combined loss narrowed to Rs 287 crore. Parent Tata Digital reported 12% revenue growth to Rs

Key facts

  • FY26 consolidated revenue: Rs 2,936 crore, up 23% from Rs 2,392 crore in FY25
  • FY26 combined net loss: Rs 287 crore
  • Tata 1mg Healthcare Solutions revenue: Rs 2,440 crore; loss: Rs 310 crore
  • Tata 1mg Technologies revenue: Rs 496 crore; net profit: Rs 23 crore
  • Combined FY26 assets: Rs 2,268 crore; liabilities: Rs 1,601 crore
  • Tata Digital FY26 revenue: Rs 35,990 crore, up 12% from Rs 32,188 crore
  • Tata Digital FY26 net loss: Rs 4,974 crore; GMV: Rs 46,515 crore

Why this matters

Tata 1mg’s growing healthcare-solutions base and profitable technology unit make it a more attractive platform for diagnostics, pharmacy, insurer and care-delivery partnerships that can accelerate margin expansion.

What to watch

  • Quarterly loss reduction relative to revenue growth, especially evidence of improving contribution margin.
  • Healthcare solutions revenue growth versus technology revenue growth and the technology unit's ability to sustain profit.
  • Diagnostics order growth, test mix and home-collection utilization rates.
  • Repeat-order rate, customer acquisition cost, average order value and medicine-delivery fulfilment cost.
  • Private-label and wellness-category share of sales.
  • Any regulatory action or policy clarification affecting online pharmacy operations, prescription validation or drug discounting.
  • Competitive discounting and delivery expansion by PharmEasy, Netmeds, Apollo 24/7 and quick-commerce platforms.
  • New Tata ecosystem integrations with Tata Neu, Tata Digital, insurers, hospitals or corporate-benefits clients.
  • Prioritize repeat prescription customers and chronic-care cohorts, where replenishment frequency lowers acquisition cost.
  • Increase cross-selling between medicines, diagnostics, doctor consultations, wellness and insurance-linked health services.
  • Expand private-label wellness, devices and nutrition offerings to improve gross margin versus branded medicine sales.
  • Use Tata Group distribution, trust and enterprise relationships to win corporate health, diagnostics and pharmacy partnerships.
  • Rationalize delivery coverage and dark-store or pharmacy-node density to improve unit economics in lower-volume markets.
  • Highlight technology-unit profitability as evidence that software, platform and B2B capabilities can subsidize or strengthen the consumer-health ecosystem.

Also reported by